Track Compugen Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Compugen Ltd. CGEN Open Compugen Ltd. in new tab

2.86 USD
P/E
7.24
EPS
0.38
P/B
2.53
ROE
44.84
Beta
2.80
Target Price
6.20 USD
Compugen Ltd. logo

Compugen Ltd.

🧾 Earnings Recap – Q3 2025

Compugen reported strong fundamentals in Q3 2025, driven by its innovation in Fc reduced anti-TIGIT treatments and promising clinical developments aimed at redefining cancer therapy.

  • Introduction of COM902, a fully owned Fc reduced anti-TIGIT monoclonal antibody, highlights Compugen's strategic advantage over Fc active competitors in clinical efficacy and safety.
  • Partnership with AstraZeneca on rilfrogostomy positions Compugen to benefit from a substantial commercial opportunity, with peak year revenue estimates exceeding $5 billion.
  • COM701, the only Fc reduced anti-PVRIG antibody in clinical development, targets unmet medical needs in platinum-sensitive ovarian cancer, enhancing Compugen's diverse pipeline.
  • Potential milestone payments of $758 million through the Gilead partnership on the innovative GS0321 program showcase significant financial upside.
  • Upcoming data readouts from key programs anticipated in 2026 could catalyze investment interest and market recognition for Compugen’s unique therapies.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 5, 2026
P/E7.24
EPS0.38
Book Value1.09
Price to Book2.53
Debt/Equity2.88
% Insiders2.081%
Growth
Revenue Growth44.77%
Estimates
Forward P/E-8.25
Forward EPS-0.33
Target Mean Price6.20

DCF Valuation

Tweak assumptions to recompute fair value for Compugen Ltd. (CGEN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Compugen Ltd. Logo Compugen Ltd. Analysis (CGEN)

Israel Health Care Official Website Stock

Is Compugen Ltd. a good investment? Compugen Ltd. (CGEN) is currently trading at 2.86 USD. Market analysts have a consensus price target of 6.20 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 7.24. This relatively low multiple may signal that Compugen Ltd. is undervalued compared to historical market norms.

Earnings Schedule: Compugen Ltd. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -0.33.

Investor FAQ

Does Compugen Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Compugen Ltd.?

Compugen Ltd. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of 0.38.

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Exchange Ticker
NGM (Sweden) CGEN
TLV (Israel) CGEN.TA

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion